Porton Advanced宣布与华龙生物合作，加速MATC细胞疗法在实体瘤治疗上的突破性进展-动脉网

Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs

CISION 等信源发布 2025-05-19 20:59



可切换为仅中文







SUZHOU,

苏州，

China

中国

，

May 19, 2025

2025年5月19日

/PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics. Porton Advanced will provide end-to-end CDMO services for Hualong's Multi-Activated T Cell (MATC) therapy, from process optimization to regulatory submission, accelerating its development progress..

/PRNewswire/ -- 领先的合同开发和制造组织（CDMO），专注于先进治疗药物（ATMPs）的Porton Advanced欣然宣布与创新癌症治疗公司Hualong Biological达成合作。Porton Advanced将为Hualong的多激活T细胞（MATC）疗法提供从工艺优化到法规提交的端到端CDMO服务，加速其研发进程。

Hualong Biological 's research team has established a strong clinical foundation for its MATC platform through multiple investigator-initiated trials (IITs), demonstrating significant therapeutic benefits across various solid tumor indications. Porton Advanced will leverage its industry-leading process development platforms, GMP manufacturing capabilities, and proven regulatory expertise to optimize the MATC therapy's CMC strategy and facilitate its transition from research to clinical development..

华隆生物的研发团队通过多个研究者发起的试验（IITs），为其MATC平台建立了强大的临床基础，展示了在各种实体瘤适应症中的显著治疗益处。Porton Advanced将利用其行业领先的工艺开发平台、GMP生产能力以及经过验证的法规专业知识，优化MATC疗法的CMC策略，并促进其从研究向临床开发的过渡。

Mingguang Huang

黄明光

, Chairman of Hualong Biological, commented: 'We are delighted to partner with Porton Advanced. Their comprehensive CDMO technical expertise and regulatory experience in cell therapy will significantly enhance our MATC program's development efficiency and IND preparation timeline. Together, we're committed to advancing this innovative therapy into clinical trials to benefit patients worldwide.'.

华龙生物董事长评论道：“我们很高兴与Porton Advanced合作。他们在细胞治疗领域的全面CDMO技术专长和监管经验将大大提升我们MATC项目的发展效率和IND准备时间。我们将共同努力，推动这一创新疗法进入临床试验，造福全球患者。”

Andrew Chen

陈安德鲁

, CFO of Porton Advanced, stated: 'Collaborating with Hualong Biological marks a strategic expansion of our CDMO services in cell therapy. We are honored to provide regulatory-compliant, high-quality MATC CMC services to support their IND application. Porton Advanced is committed to supporting partners through our integrated technology platform and regulatory experience to bring cutting-edge therapies to patients faster.'.

Porton Advanced的首席财务官表示：“与华龙生物的合作标志着我们在细胞治疗领域的CDMO服务的战略扩展。我们很荣幸能够提供符合法规要求的高质量MATC CMC服务，以支持他们的IND申请。Porton Advanced致力于通过我们的综合技术平台和监管经验来支持合作伙伴，更快地将前沿疗法带给患者。”

About Hualong Biological

关于华龙生物

Founded in 2012, Henan Hualong Biological is a national high-tech enterprise in

成立于2012年，河南华龙生物是一家国家级高新技术企业。

China

中国

specializing in cell technology development and applications. Aligned with its strategic vision of integrating cell storage, research, therapeutic development, and clinical applications, Hualong Biological primarily focuses on cell banking, cell therapy development, and related cell technology services..

专注于细胞技术的开发和应用。秉承其细胞储存、研究、治疗开发和临床应用相结合的战略愿景，华龙生物主要聚焦于细胞银行、细胞治疗开发及相关的细胞技术服务。

The company has established advanced expertise in immune and stem cell technologies, with several core technical parameters ranking among industry leaders. Its comprehensive platform addresses the full spectrum of cell therapy development, from fundamental research to clinical implementation. Through continuous technological innovation and strategic market expansion, Hualong Biological has emerged as a leading cell therapy enterprise in .

该公司在免疫和干细胞技术方面建立了先进的专业知识，多个核心工艺参数位居行业领先地位。其综合性平台覆盖了从基础研究到临床实施的细胞治疗开发全流程。通过持续的技术创新和战略性市场拓展，华隆生物已成为国内细胞治疗领域的领先企业。

Henan Province

河南省

. The company remains committed to consolidating its influential position within the cellular technology industry.

公司仍然致力于巩固其在细胞技术行业中的有影响力的地位。

About Porton Advanced

关于Porton Advanced

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in

Porton Advanced Solutions是领先CDMO公司Porton Pharma Solutions的子公司。Porton Advanced总部位于

Cranbury, New Jersey

新泽西州克兰伯里

, and two GMP sites in Suzhou,

，以及苏州的两个GMP站点，

China

中国

, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization..

，为ATMP提供端到端的CDMO解决方案。我们的服务涵盖细胞库构建、工艺与分析方法开发、cGMP生产到灌装和成品等环节，覆盖药物开发的不同阶段，包括早期研究、研究者发起的试验（IIT）、新药临床试验申请（IND）、临床试验、新药申请（NDA）以及商业化。

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV,etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sqft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms.

Porton Advanced 开发了专门的 CRO 和 CDMO 平台，专注于质粒、病毒载体（慢病毒载体、腺病毒载体、AAV 等）、细胞治疗 CMC 服务（包括 CAR-T、TCR-T、CAR-NK、HSC、外泌体等）以及核酸疗法。我们拥有最先进的、符合 GMP 标准的设施，占地达 215,000 平方英尺，配备了 10 条病毒载体生产线、12 个符合 GMP 标准的细胞治疗生产套间（包括 2 个用于感染供体的套间）以及众多洁净室。

As of now, we have successfully supported our clients to secure 18 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into .

截至目前，我们已经成功支持客户获得了18项来自NMPA、FDA和Medsafe的全球IND批准，并有5个正在进行的I/II期ATMP项目。此外，Porton Advanced还成功支持了多个海外临床阶段管线的顺利过渡。

China

中国

。

Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.

保诺科技致力于以客户为中心，为我们的客户提供卓越的全球端到端CDMO服务，助力有效药物早日惠及公众。

For more information about Porton Advanced, please visit:

有关 Porton Advanced 的更多信息，请访问：

www.portonadvanced.com

。

SOURCE Porton Advanced Solutions

源端口：Porton Advanced Solutions

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+